Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Joseph J. Larosa Sells 1,866 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the completion of the transaction, the executive vice president now owns 37,937 shares in the company, valued at $41,311,496.15. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Regeneron Pharmaceuticals Stock Up 1.8 %

Shares of REGN stock traded up $19.78 during trading on Friday, reaching $1,100.05. The company’s stock had a trading volume of 465,222 shares, compared to its average volume of 471,526. The business has a fifty day moving average price of $1,010.86 and a 200-day moving average price of $962.46. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The company has a market cap of $121.21 billion, a price-to-earnings ratio of 31.91, a price-to-earnings-growth ratio of 2.21 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a one year low of $715.22 and a one year high of $1,106.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The business had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Evercore ISI assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 target price on the stock. Morgan Stanley decreased their price target on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research report on Thursday. JPMorgan Chase & Co. raised their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research report on Monday, June 17th. UBS Group lifted their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. Finally, TD Cowen lifted their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,038.77.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Eudaimonia Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 1.2% in the fourth quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock valued at $803,000 after acquiring an additional 11 shares during the last quarter. Team Hewins LLC lifted its stake in shares of Regeneron Pharmaceuticals by 2.5% during the 1st quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 11 shares during the last quarter. Angeles Wealth Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 3.5% during the 1st quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 11 shares during the last quarter. Drive Wealth Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 4.0% during the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 12 shares during the last quarter. Finally, MCF Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.